Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.8 USD | +8.25% | -2.50% | -19.64% |
10/05 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
09/05 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.64% | 2.85B | |
+6.68% | 111B | |
+10.99% | 106B | |
-13.09% | 22.24B | |
+0.52% | 21.25B | |
-4.13% | 18.97B | |
-37.85% | 18.52B | |
-10.50% | 16.81B | |
+39.11% | 12.54B | |
-24.76% | 8.09B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $60 From $77, Maintains Outperform - Speculative Risk Rating